Takeda To Purchase IDM Pharma To Boost Oncology Business
This article was originally published in PharmAsia News
Takeda Pharmaceutical May 18 announced a buyout plan to acquire U.S. biopharmaceutical company IDM Pharma. Takeda plans to pay $75 million to obtain all outstanding shares of the Nasdaq-listed company. IDM has obtained approval in the EU for Mepact (mifamurtide), the first treatment approved for osteosarcoma. Through the buyout, Takeda plans to market the drug through marketing branches in Europe and expand its oncology business in the European market. (Click here for more - Japanese language
You may also be interested in...
Public Company Edition: Four health care special purpose acquisition vehicles went public and two others announced mergers, but only one biopharma firm priced an IPO during the week of 19-23 October. Replimune’s $250m offering led recent FOPOs.
Wholesalers are given three more years to set up electronic systems to verify saleable returns under another reprieve from the FDA. Yet the reprieve does not extend to manufacturers, who must respond within 24 hours to wholesalers’ requests to manually verify that a returned product is not suspect.
Agency explains how it will model vaccine authorization process on its licensing process for matters like inspections and lot release.